Latest Commercialisation Strategies News

GCM Corporation has launched its first Very High Density (VHD) heat sink product line, marking a pivotal step from development to commercial sales in thermal management technology.

Papyrus Australia has commissioned its Adelaide Rapid Prototyping & R&D Facility, marking a key step in validating its pulp technology and progressing towards commercial production. The company also released its interim financials and reported stable cash flow supporting ongoing operations.

InFocus Group Holdings has completed Codexa, a proprietary sweepstakes casino platform targeting the booming US market, with plans for licensing and potential sale.

GCM Corporation has completed the full transfer of its proprietary Very High Density (VHD) technology, gaining exclusive global ownership with payments tied to future revenue milestones.

ClearVue Technologies reported a 9% reduced half-year loss of $5.25 million, while pushing forward with significant advancements in its solar glass technology and expanding global licensing partnerships.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Firebird Metals has locked in exclusive global rights to five critical LMFP patents, solidifying its position in the lithium-ion battery materials market and paving the way for its Australian Demonstration Plant.

Papyrus Australia Limited reported a reduced half-year loss and marked a significant commercial milestone with a $4.2 million supply contract, advancing its transition from technology development to early-stage commercialisation.

Temas Resources has inked a Letter of Intent to validate its patented Regenerative Chloride Leach technology on a major refractory gold deposit, paving the way for a joint venture to commercialise the platform in Western North America.

GCM Corporation is advancing its commercialisation strategy with multiple prototypes across key global markets and sectors, aiming for revenue in the first half of 2026.

4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.